UBS Group AG Lowers Holdings in Bruker Corporation $BRKR

UBS Group AG trimmed its position in shares of Bruker Corporation (NASDAQ:BRKR) by 29.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,000,467 shares of the medical research company’s stock after selling 413,452 shares during the quarter. UBS Group AG’s holdings in Bruker were worth $47,132,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Allworth Financial LP increased its position in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Spire Wealth Management boosted its stake in Bruker by 85.3% during the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares during the last quarter. CWM LLC increased its holdings in shares of Bruker by 49.8% in the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 51.5% during the second quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 942 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Bruker by 79.7% during the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 1,230 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 results beat estimates: Bruker reported EPS of $0.31 vs. consensus $0.23 and revenue of $823.4M vs. $795.6M, with revenue +2.7% year-over-year — the top-line beat and EPS outperformance are the primary positive catalysts. Zacks: Bruker Surpasses Q1 Estimates
• Neutral Sentiment: FY?2026 guidance essentially in line with expectations: management set EPS guidance of $2.10–$2.15 (consensus ~2.12) and revenue guidance near ~$3.6B — guidance is not materially above Street forecasts but removes uncertainty. Earnings Presentation
• Neutral Sentiment: Management materials and call available: Bruker posted its slide deck and hosted the earnings call, giving investors access to segment detail and near-term catalysts (service instrument demand, product cycles). Those details support the guidance but did not materially change the outlook. MarketBeat: Q1 Earnings / Call
• Negative Sentiment: Profitability concerns remain: despite the beat, GAAP net margin was slightly negative and Q1 EPS declined versus $0.47 a year ago — a reminder that earnings mix and margin recovery remain watching points for investors. MarketBeat: Q1 Details
• Negative Sentiment: Pre-earnings concerns and insider activity noted: some coverage flagged “earnings jitters” and insider selling ahead of results, which could elevate volatility and be a near-term headwind if sentiment shifts. Yahoo: Insider Selling / Earnings Jitters

Wall Street Analysts Forecast Growth

Several research firms recently commented on BRKR. Barclays reiterated an “overweight” rating and issued a $53.00 price objective on shares of Bruker in a report on Thursday. Citigroup restated a “neutral” rating on shares of Bruker in a research note on Thursday. The Goldman Sachs Group reduced their price target on shares of Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research note on Friday, February 13th. Jefferies Financial Group set a $50.00 price objective on shares of Bruker in a report on Thursday, February 12th. Finally, UBS Group restated a “neutral” rating and set a $49.00 price objective on shares of Bruker in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $50.00.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 27.20% of the company’s stock.

Bruker Trading Up 11.3%

Bruker stock opened at $42.30 on Thursday. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $56.22. The firm has a market capitalization of $6.44 billion, a price-to-earnings ratio of -282.00, a P/E/G ratio of 2.28 and a beta of 1.12. The firm has a 50 day moving average of $37.18 and a 200 day moving average of $42.01. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio is currently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.